CalliSpheres^® microsphere transarterial chemoembolization combined with ¹²⁵I brachytherapy for patients with non-small-cell lung cancer liver metastases.

ABSTRACT:

Objective

Poor prognosis and limited treatments of liver metastases from non-small-cell lung cancer (NSCLC) after radical surgery are critical issues. The current study aimed to evaluate the efficacy and safety of CalliSpheres^® microsphere transarterial chemoembolization (CSM-TACE) plus ¹²⁵I brachytherapy in these patients.

Methods

A total of 23 patients with liver metastases from NSCLC after radical surgery were included. All patients received CSM-TACE 1-3 times, then ¹²⁵I brachytherapy was carried out following the last CSM-TACE. Complete response (CR), objective response rate (ORR), disease control rate (DCR), survival, and adverse events were evaluated.

Results

CR, ORR and DCR were 43.5%, 87.0%, and 100%, respectively, at three mon

SUBMITTER: Zhao G 

PROVIDER: S-EPMC9413194 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature